CTOs on the Move


 
Vaxin is a clinical stage immunotherapeutic biotechnology company located in Montgomery County, MD with additional operating sites in London, UK and Strasbourg, France. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Vaxin is able to rationally design and rapidly develop immunotherapeutic products tailored to address the a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer with fundamental advantages over competing products. Our mission at Vaxin is to protect and preserve public health by providing effective and safe vaccines that prevent disease outbreak.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vaxin.com
  • 19 Firstfield Road
    Gaithersburg, MD USA 20878
  • Phone: 240.654.1450

Executives

Name Title Contact Details

Similar Companies

Employers Drug Program Management

Employers Drug Program Management is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alliance Analytical

Alliance Analytical is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bryan LGH

Bryan LGH is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gilva Biotechnology

Gilva Biotechnology is a Belmont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Capsida

We are a biotechnology company creating a new class of targeted gene therapies for debilitating and life-threatening genetic disorders in both central nervous system (CNS) and non-CNS indications. Current gene therapy approaches have shown dramatic efficacy in several rare diseases but are hindered by imprecise targeting. The inability to selectively transduce specific cells and tissues effectively drives administration of higher doses and resulting safety liabilities. We are addressing these concerns with our proprietary adeno-associated virus (AAV) engineering platform that generates capsids optimized to target specific tissues and cells in the disease organ while limiting transduction of tissues and cells not relevant to the target disease. Through our next-generation AAV platform combined with cargo development and state-of-the-art manufacturing, we are tackling monogenetic and sporadic CNS and non-CNS disorders that have previously been challenging to address.